Polaris Group (TPE:6550)
Taiwan · Delayed Price · Currency is TWD 9.92
+0.02 (0.20%)
Sep 16, 2026, 2:39 PM CST
Polaris Group Revenue
Polaris Group had revenue of 7.09M TWD in the quarter ending June 30, 2026, a decrease of -15.63%. This brings the company's revenue in the last twelve months to 67.95M, up 6.15% year-over-year. In the year 2025, Polaris Group had annual revenue of 40.60M, down -62.05%.
Revenue (ttm)
67.95M
Revenue Growth
+6.15%
P/S Ratio
130.63
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.60M | -66.40M | -62.05% |
| Dec 31, 2024 | 107.00M | 99.52M | 1,330.29% |
| Dec 31, 2023 | 7.48M | 1.04M | 16.18% |
| Dec 31, 2022 | 6.44M | -8.60M | -57.19% |
| Dec 31, 2021 | 15.04M | 5.63M | 59.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Adimmune | 1.37B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| TCM Biotech International | 701.63M |
| Tanvex BioPharma | 657.56M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| Locus Cell | 19.40M |